Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its ...

Emory’s Sagar Lonial, MD, a world-class leader in his specialty, harnesses teamwork to advance the treatment of multiple ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

Patients have been asking me about a recently published article that suggests a "'potential cure"' for myeloma is at hand.

The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of VRd for multiple myeloma.

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...